Epithelial barrier hypothesis of allergic disease
epithelial_barrier_hypothesis
CANONICAL
Evidence: 1
Evidence balance
1 support
Allergic/type 2 inflammatory diseases share an upstream epithelial barrier defect that, by permitting transepithelial allergen and microbial penetration, initiates type 2 sensitization and allergic disease across tissues. The defect appears to pre-date atopy, implying barrier protection as a prevention target.
Epithelial Barrier Insult and Junctional Disruption
trigger
External insults (allergen-associated proteases, irritants, pollutants, microbes, mechanical injury) and/or intrinsic defects in barrier components (tight-junction proteins, antiproteases, structural proteins such as filaggrin in the skin) disrupt tight and adherens junctions across barrier epithelia. This is the initiating state shared by skin, airway, gut, and esophageal allergic disease.
Used by disorders
Asthma
as House Dust Mite Allergen Protease-Induced Epithelial Oxidant Signaling
Downstream
-
Loss of Terminal Differentiation and Reduced Junctional Integrity
Show evidence (2 references)
"Barrier loss can result from defects in several essential components, including tight junction proteins, protective antiproteases, structural elements such as filaggrin in the skin"
Cross-tissue review enumerates the shared barrier components whose defect or disruption initiates barrier loss across allergic diseases.
"Allergens can contain proteases and have been shown to disrupt epithelial tight junctions"
Identifies allergen-associated protease activity as a generic external insult that disrupts epithelial tight junctions.
Loss of Terminal Differentiation and Reduced Junctional Integrity
amplifier
Across allergic disease, irrespective of the affected organ, the epithelial barrier is skewed toward loss of terminal differentiation, reduced junctional integrity, and impaired innate defense. This dysregulated state appears to pre-date atopy, marking it as a predisposing host trait rather than only a downstream consequence of inflammation.
Downstream
-
Increased Transepithelial Allergen Penetration and Innate Immune Activation
Show evidence (3 references)
"in patients with allergic disease, regardless of tissue location, the
homeostatic balance of the epithelial barrier is skewed toward loss of
differentiation, reduced junctional integrity, and impaired innate defense."
States the conserved, tissue-independent barrier-dysfunction phenotype that this module abstracts.
"Importantly, epithelial dysfunction characterized by these traits appears to
pre-date atopy and development of allergic disease."
Supports barrier dysfunction as a predisposing trait preceding atopy.
"In asthmatic patients abnormalities in many aspects of epithelial
barrier function have been identified."
Confirms the airway arm of the conserved barrier defect (asthmatic bronchial epithelium), substituting for the generic epithelium.
Increased Transepithelial Allergen Penetration and Innate Immune Activation
central effector
With the barrier predisposed to disruption, allergens and microbes gain paracellular access across the epithelium to the underlying lamina propria, where pattern-recognition-receptor signaling and epithelial alarmins drive innate immune activation and antigen-presenting-cell stimulation. This is the central convergence point and the canonical conformance target.
Downstream
-
Type 2 Sensitization and IgE Class Switch
Show evidence (2 references)
"Antigen penetration through a
compromised barrier likely leads to increased innate immune responses,
antigen-presenting cell stimulation, and priming of overt cutaneous disease."
Describes antigen penetration through the disrupted barrier driving innate immune and antigen-presenting-cell activation.
"microorganisms and antigens can gain access between epithelial cells through the basement membrane to the underlying lamina propria and connective tissue. Penetration of microbes triggers strong innate immune responses by PRR on epithelial cells and immune cells"
Mechanistic statement that barrier predisposition permits transepithelial antigen/microbe access and PRR-driven innate immune activation.
Type 2 Sensitization and IgE Class Switch
effector
The innate-activated, TH2-promoting microenvironment drives T-cell/B-cell interactions in regional lymph nodes that lead to excessive IgE class switch, establishing allergen-specific sensitization characteristic of the allergic diathesis.
Downstream
-
Allergic Disease Initiation and the Atopic March
Show evidence (2 references)
"In
a TH2-promoting environment, T-cell/B-cell interactions occurring in regional
lymph nodes lead to excessive IgE switch."
Describes the TH2-driven T/B-cell interaction producing excessive IgE class switch downstream of barrier-enabled sensitization.
"Subsequent sensitization and activation of adaptive immune responses can result, including type 2 immune responses of relevance to the allergic diathesis."
Connects barrier-enabled antigen access to adaptive type 2 sensitization.
Allergic Disease Initiation and the Atopic March
outcome
Barrier-initiated sensitization manifests as allergic disease at the affected barrier (e.g., atopic dermatitis in skin, asthma in airway, eosinophilic esophagitis in esophagus) and can spread systemically to initiate the atopic march — the sequential development of food allergy, asthma, and allergic rhinitis. Because the barrier defect is upstream, barrier-supplementing interventions (e.g., emollients) are proposed primary prevention.
Show evidence (2 references)
"spreads beyond the skin to initiate the atopic march,
which includes food allergy, asthma, and allergic rhinitis"
Defines the atopic-march outcome: barrier-initiated allergic disease progressing across organs (food allergy, asthma, allergic rhinitis).
"Possible primary
interventions to prevent AD are focusing on improving skin barrier integrity,
including supplementing barrier function with moisturizers."
Supports barrier-supplementation (emollients) as upstream primary prevention, consistent with the barrier-first causal direction.